跳至主要内容
临床试验/ISRCTN00691795
ISRCTN00691795已完成未知

Protection against Incidences of Serious Cardiovascular Events Study with daily fish oil supplementation in dialysis patients

Toronto General Research Institute0 个研究点目标入组 1,310 人开始时间: 2013年11月5日最近更新:
适应症

试验速览

阶段
未知
状态
已完成
发起方
入组人数
1,310

研究概览

简要总结

2024 Protocol article in https://doi.org/10.1136/bmjopen-2023-072239 (added 11/01/2024)

研究设计

研究类型
Interventional

入排标准

性别
All

入选标准

  • 1. Adult (age >18 years) men and women with end-stage kidney disease (ESKD) who require chronic hemodialysis (HD) 3 or 4 times/week of duration 5 hours/session or less
  • 2. Clinically stable (no hospitalization or emergency room [ER] visit 1 month before enrolment)

排除标准

  • 1. Reversible, acute renal failure, likely with recovery of renal function
  • 2. Pregnancy
  • 3. Active malignancy
  • 4. Active major bleed within 1 month of enrolment
  • 5. Blood pressure (BP) higher than 180/120 (malignant level)
  • 6. Receiving more than two antiplatelet agents or anticoagulants i.e. use of ASA and coumadin is not an exclusion
  • 7. Life expectancy of less than 6 months (i.e. palliative dialysis patients)
  • 8. Implanted implantable cardioverter-defibrillators (ICD) or planned ICD placement within the year
  • 9. Involvement in another drug trial
  • 10. Current fish oil ingestion at the time of randomization
  • 11. Any known allergy to fish or fish products
  • 12. Unable to provide written informed consent (self or legal representative)

研究者

发起方
Toronto General Research Institute

相似试验